Dr. Jonathan Usuka shares how Sapient is helping reshape how biopharma brings life-changing therapies to patients.
Discussing how omics studies can answer more of the fundamental questions that drive successful drugs to market.
Why is embracing multi-omics the leap the industry needs to make to improve therapeutic development? We discuss.
Using large-scale multi-omics and clinical datasets to accelerate R&D timelines, de-risk programs & improve probability of success.
How multi-omics profiling of disease accelerates new target discovery, clinical trials, and alignment of patients & therapies.
How multimodal longitudinal datasets can be leveraged to improve therapeutic development and patient outcomes.
Discussing how multiple innovation cycles are aligning in the "year of proteomics" to drive better, faster drug development.
How is the ability to more broadly probe human biology enabling more precise & targeted drug development?
A conversation on the future of biomarker discovery and mass spectrometry & what it means to go 'beyond the genome'.
Talking multiomics data and how it can take pharmacogenomics to the next level such as in predicting patient response.
Discussing how next-gen multiomics is enabling drug development transformation in the post-COVID era.
Discussing questions such as, what can your zip code tell us about your health that your genetic code cannot?
